Maintaining bone strength after menopause A 48-week randomised, double-blind, placebo-controlled trial with 60 postmenopausal women with osteopenia revealed remarkable bone health benefits [23]
Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
Long-term safety studies (beyond 6 months) do not appear to have been conducted for oral glutathione [1]
However, in order to realize the full therapeutic potential of ferroptosis-based therapies, it is critical that we first acquire a fundamental understanding of the biochemical and molecular pathways regulating ferroptosis, and its biological roles within physiological contexts
R., Borner, T., & De Jonghe, B
